Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Harbor vs TD Tele-Doc Weight Loss

Harbor
Graded #87

Higher grade

vs+10
TD Tele-Doc Weight Loss
Graded #288

Lower grade

The verdict

Harbor takes it — 71.8/100 to 61.8/100.

Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHarbor +28
73
45
Dose & formulationHarbor +11
64
53
Clinical oversightHarbor +1
89
88
Labs & monitoringTD Tele-Doc Weight Loss +2
63
65
FulfillmentHarbor +13
81
68
Contract termsTD Tele-Doc Weight Loss +8
47
55
Harbor · left barTD Tele-Doc Weight Loss · right bar

The numbers

MetricHarborTD Tele-Doc Weight Loss
WeighScore71.8/10061.8/100
GradeCC
Scorecard rank#87#288
Semaglutide$99/mo (starting dose, compounded)Not disclosed
Tirzepatide$149/mo (starting dose, compounded)Not disclosed
CoverageCoverage not published2 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Harbor

Graded #87 · C

Strengths

  • Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
  • LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
  • 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
  • 12-Month Money Back Guarantee if you don't reach your weight-loss goal
  • HSA/FSA eligible; no hidden fees, no insurance billed

Where it loses points

  • Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
  • Dietitian support offered only post-program (maintenance phase), not during active treatment
  • State-specific consultation types vary; nationwide availability unconfirmed for all states
  • No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
  • Newer brand; success rate and member counts are on-site claims, not third-party verified
TD Tele-Doc Weight Loss

Graded #288 · C

Strengths

  • Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
  • 100% virtual — weekly appointments with board-certified MDs from home; no travel required
  • Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
  • In-network with most commercial insurance plans; may cover visits and monitoring equipment
  • Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)

Where it loses points

  • No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
  • Telehealth available only in Virginia and Maryland; no national reach confirmed
  • No Medicare or Medicaid accepted; limited to commercial insurance plans only
  • No LegitScript certification found; compounded availability and specific pricing undisclosed on site
  • Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard